Supernus Pharmaceuticals Income from Discontinued Operations 2011-2025 | SUPN
Supernus Pharmaceuticals income from discontinued operations from 2011 to 2025. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
Supernus Pharmaceuticals Annual Income from Discontinued Operations
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$0 |
| 2022 |
$0 |
| 2021 |
$0 |
| 2020 |
$0 |
| 2019 |
$0 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$0 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$77 |
| 2010 |
$1 |
Supernus Pharmaceuticals Quarterly Income from Discontinued Operations
(Millions of US $) |
| 2025-03-31 |
|
| 2024-12-31 |
|
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
$76 |
| 2011-09-30 |
$0 |
| 2011-06-30 |
$2 |
| 2011-03-31 |
$-1 |
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.879B |
$0.662B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
